What Is Synthetic Biology?
Synthetic biology — often shortened to synbio — is the discipline of designing and engineering biological systems to perform functions that do not exist in nature. If traditional biology is about understanding how life works, synthetic biology is about using that understanding to build new things.
At its core, synbio treats living cells as programmable machines. Just as software engineers write code to make computers perform tasks, synthetic biologists write genetic code — DNA sequences — to make cells produce specific proteins, chemicals, or behaviors. The field draws on genetics, molecular biology, engineering, and computer science to create organisms that can manufacture drugs, detect diseases, produce sustainable materials, or clean up environmental contamination.
The term gained currency in the early 2000s, but the underlying principles are older. Humans have been modifying organisms through selective breeding for thousands of years. What makes modern synthetic biology different is precision: instead of waiting generations for desired traits to emerge through breeding, scientists can now design genetic circuits from scratch and insert them into cells, producing results in days or weeks.
Key Applications
Medicine and Therapeutics
Synthetic biology is already transforming how medicines are made. One of the field's landmark achievements was the engineering of yeast to produce artemisinic acid, a precursor to the antimalarial drug artemisinin, which had previously been extracted from sweet wormwood plants at great expense. This work, led by Jay Keasling at UC Berkeley and supported by the Gates Foundation, demonstrated that synthetic biology could stabilize the supply of a life-saving drug.
Today, synbio approaches are used to produce a growing list of therapeutics. Engineered cells can manufacture insulin, human growth hormone, and monoclonal antibodies more efficiently than traditional methods. More ambitiously, researchers are designing living therapeutics — engineered bacteria that can be ingested or injected to detect and treat disease from inside the body. Companies like Synlogic have developed engineered E. coli strains designed to treat metabolic diseases like phenylketonuria (PKU) by breaking down toxic metabolites in the gut.
CAR-T cell therapies, which use engineered immune cells to fight cancer, represent another intersection of synthetic biology and medicine. The genetic circuits inserted into T cells — including chimeric antigen receptors, safety switches, and cytokine circuits — are products of synthetic biology design principles.
Agriculture and Food
The food and agriculture sector is one of synbio's most commercially active arenas. Engineered microorganisms are being used to produce proteins, fats, flavors, and fragrances that traditionally required farming, animal husbandry, or petroleum-based chemistry.
Precision fermentation uses engineered yeast or bacteria to produce specific proteins — including whey, casein, collagen, and egg white proteins — without animals. Companies like Perfect Day (dairy proteins), The Every Company (egg proteins), and Impossible Foods (heme for plant-based meat) are scaling this approach commercially.
Nitrogen fixation is another frontier. Pivot Bio has engineered soil microbes that produce nitrogen fertilizer directly at plant roots, reducing dependence on synthetic fertilizers produced by the energy-intensive Haber-Bosch process. This could significantly cut agriculture's carbon footprint.
Crop protection using synbio-derived biopesticides offers alternatives to chemical pesticides, with companies developing engineered microbial products that target specific pests while leaving beneficial insects unharmed.
Materials and Manufacturing
Some of the most striking synbio applications involve engineering organisms to produce materials that would be difficult or impossible to manufacture chemically.
Spider silk — one of nature's strongest materials — has been notoriously difficult to produce at scale because spiders are territorial and cannibalistic, making farming impractical. Companies like Bolt Threads and Spiber have engineered yeast and bacteria to produce silk proteins through fermentation, enabling production of textiles and composites with remarkable strength-to-weight ratios.
Bioplastics produced by engineered microorganisms offer biodegradable alternatives to petroleum-based plastics. These organisms convert renewable feedstocks like plant sugars into polymers like polyhydroxyalkanoates (PHAs) that decompose naturally in the environment.
Biofuels remain an active area, with engineered algae and yeast strains producing ethanol, butanol, and biodiesel from non-food biomass. While cost competitiveness with fossil fuels remains challenging, advances in metabolic engineering continue to improve yields.
The Companies Shaping the Field
Ginkgo Bioworks is the largest dedicated synbio company, operating what it calls a "cell programming platform." Ginkgo designs custom microorganisms for clients across pharmaceuticals, agriculture, food, and industrial chemicals. Its foundry model — high-throughput, automated strain engineering — aims to make biological engineering as scalable and repeatable as software development. The company went public via SPAC in 2021 and has since focused on expanding its platform and customer base.
Twist Biosciences manufactures synthetic DNA — the raw material that synthetic biologists need to build their genetic constructs. As the cost of DNA synthesis has fallen (from dollars per base pair to pennies), Twist has positioned itself as a critical supplier to the field.
Zymergen (acquired by Ginkgo in 2022), Amyris (focused on sustainable ingredients), and Codexis (enzyme engineering) represent other nodes in the synbio ecosystem, each tackling different aspects of the design-build-test-learn cycle.
Ethical Considerations
The ability to engineer life raises questions that extend well beyond the laboratory.
Biosecurity
As DNA synthesis becomes cheaper and more accessible, the risk of misuse grows. It is becoming technically feasible to synthesize the genomes of dangerous pathogens from publicly available sequences. The synbio community and DNA synthesis companies have responded with screening protocols — checking orders against databases of known pathogen sequences — but the system is not foolproof. International frameworks for governing dual-use biological research remain underdeveloped.
Environmental Release
Releasing engineered organisms into the environment — whether nitrogen-fixing microbes into soil or gene-drive mosquitoes into the wild — carries ecological risks that are difficult to predict or reverse. Gene drives, which use CRISPR to spread engineered traits through wild populations, are being developed to combat malaria by suppressing mosquito populations, but the potential for unintended ecological consequences makes field trials controversial.
Equity and Access
The benefits of synthetic biology risk being concentrated in wealthy nations and large corporations. If precision fermentation displaces traditional agriculture, millions of small farmers in developing countries could lose their livelihoods. Ensuring that synbio's benefits are broadly shared requires proactive policy — not just technological innovation.
Intellectual Property
The field's heavy reliance on patents and proprietary platforms raises concerns about who controls access to biological engineering tools. Open-source movements like the iGEM (International Genetically Engineered Machine) competition and the BioBricks Foundation promote free sharing of standardized genetic parts, but commercial pressures often push in the opposite direction.
The Road Ahead
Synthetic biology is at the stage that software was in the 1980s — the tools are maturing, costs are falling exponentially, and the range of applications is expanding faster than most observers anticipated. The global synbio market is projected to exceed $80 billion by 2030, driven by demand for sustainable manufacturing, novel therapeutics, and food security solutions.
The field's long-term promise is nothing less than a new industrial revolution — one where biology replaces chemistry and petrochemistry as the primary platform for making things. Whether that promise is realized responsibly will depend as much on governance and ethics as on science and engineering.
